Navigation Links
Radiesse(R) Dermal Filler Featured Prominently in Journal of Dermatologic Surgery Special Issue on Fillers
Date:6/26/2008

procedures performed in dermatology and plastic surgery practices. BioForm Medical's lead product is Radiesse(R) dermal filler, a long-lasting filler for use in facial aesthetics. BioForm Medical is developing several future aesthetics products, including a radiofrequency treatment to reduce nerve function in the forehead, a sclerotherapy treatment for spider veins, and a surgical adhesive for brow lifts. For more information about BioForm, please visit http://www.bioform.com.

Radiesse(R) is a registered trademark of BioForm Medical, Inc.

Contact:

Adam Gridley

650.286.4025

Vice President, Corporate Development

BioForm Medical, Inc.


'/>"/>
SOURCE BioForm Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
2. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
3. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
4. Non-Safety-Related Voluntary Recall of a Limited Portion of DAYTRANA(TM) (Methylphenidate Transdermal System) Patches Announced
5. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
6. Osteotechs Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
7. lifesDHA(TM) Featured in New Ricos(R) Cheese Sauce
8. Boydens Summit Practice Featured in the September Issue of New Jersey Business Magazine
9. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
10. Synvista Therapeutics to be Featured on Wallst.net
11. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Decision ... frequently cited advantages of Otezla are its oral ... profile, as reported by surveyed rheumatologists. Otezla was ... for the treatment of active psoriatic arthritis in ... current standard of care includes conventional oral treatments ...
(Date:7/1/2015)... Bermuda , July 1, 2015  Axovant ... company focused on the treatment of dementia, today ... briefing on July 22 at 5:45 p.m. EDT ... the Alzheimer,s Association International Conference 2015 (AAIC). ... remarks: , Dr. Lawrence Friedhoff ...
(Date:7/1/2015)... ... 01, 2015 , ... Apex Therapeutics announced today that company CEO, David Broecker ... , The presentation took place on Tuesday, June 16 and provided an update ... APX3330 for the treatment of pancreatic cancer. A copy of the company overview ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2
... Net Income & EBITDA (as adjusted) Increases of 21% ... ... Mac-Gray Corporation,(NYSE: TUC ), the nation,s premier provider of laundry ... first quarter ended March 31, 2008., Mac-Gray reported record first-quarter revenue ...
... Dana-Farber and Colorado Treating Patients with ENMD-2076, ... Inc. (Nasdaq:,ENMD), a clinical-stage pharmaceutical company developing ... diseases, today announced that,Dana-Farber Cancer Institute has ... conducting a Phase 1 study of ENMD-2076 ...
... Wash., May 8 BioLife Solutions Inc.,(OTC Bulletin ... proprietary,hypothermic storage and cryopreservation media products for cells, ... for CryoStor,cryopreservation media has been accepted by the ... Chairman and Chief Executive Mike Rice commented: "We ...
Cached Biology Technology:Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 2Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 3Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 4Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 5Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 6Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 7Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 8Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 9Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 10Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 11Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 12Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 13Mac-Gray Corporation Announces First-Quarter 2008 Financial Results 14Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 2Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor 3BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 2BioLife Solutions Announces FDA Master File Acceptance for CryoStor(TM) Pre-formulated Cryopreservation Media 3
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... June 25, 2015  TAKE Solutions Ltd., a global ... the United States Patent and Trademark Office (USPTO) for ... leverages TAKE Solutions, Clinical Accelerators to reduce the time ... compared to standardization without the accelerators), thus reducing time ... At the heart of the patented Clinical ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... In the largest prospective study to date of children ... (ASD) compared to children without ASD, researchers found two ... the children with ASD. Published in the journal ... development, children who display early signs of ASD show ...
... A group of researchers in Israel, the United States and ... of "regenerative medicine," outlining for the first time connections ... and facial muscles. Some of these problems are surprisingly ... congenital heart defect. This basic research will provide a road ...
... Biking, running and walking are all good for you. But the ... from other joint problems or injuries. What to do? Just add ... found that people who used an immersible ergocycle basically an ... workout to using a typical stationary bike. "If you can,t ...
Cached Biology News:Distinct developmental patterns identified in children with autism during their first 3 years 2Distinct developmental patterns identified in children with autism during their first 3 years 3Researchers identify genetic basis of cardiac, craniofacial birth defects 2Researchers identify genetic basis of cardiac, craniofacial birth defects 3Everyone in the pool! Water workouts just as good as on land 2
... Form: buffered aqueous solution. ... from complex carbohydrates and glycoproteins. It is ... conditions where the pH must be neutral ... Unit Definition: One ...
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
...
... to offer the ATTO-TAG series of ... primary amines. Developed by Novotny and ... reagents are similar to the important ... anthracene-2,3-dicarboxaldehyde, all of which are also ...
Biology Products: